The National Pharmaceutical Pricing Authority (NPPA) has fixed/revised the prices of 308 formulations. The price fixation includes ceiling Prices for 238 formulations and non-ceiling prices of 70 packs, including 31 imported insulin formulations.

According to NPPA statement, the price fixation/revision cases also cover derivative formulation packs based on the bulk drugs Chloroquine Phosphate, Norfloxacin, Ranitidine, Naproxen, Erythromycin Base, Erythromycin Stereate, Erythromycin Ethyl Succinate, Vitamin E, Vitamin C, Combination of Vitamin E & C, Detropropoxyphene Hydrochloride and Cefadroxyl Monohydrate. In the case of all these formulations prices have been suo-moto reduced. This also includes 81 cases of Betamethasone Dipropionate and certain others formulations, formulated namely by Cipla, Sun Pharma, Wockhardt, Alkem and USV fixed after receipt of complaints and on the bases of available information.

Apart from the cases of price fixation / revision, NPPA has also fixed packing material cost norms in respect of metered dose inhalers. With this, the NPPA has fixed/revised the prices of 720 formulations in calendar year 2005 which is a record.